AUTHOR=Wang Ying , Yu Qian , Tian Yuan , Ren Shiying , Liu Liping , Wei Chaojie , Liu Renli , Wang Jing , Li Dong , Zhu Kun 

TITLE=Unraveling the impact of nitric oxide, almitrine, and their combination in COVID-19 (at the edge of sepsis) patients: a systematic review

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 14 - 2023

YEAR=2024

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1172447

DOI=10.3389/fphar.2023.1172447

ISSN=1663-9812

ABSTRACT=<p><bold>Introduction:</bold> During the coronavirus disease 2019 (COVID-19) pandemic, a large number of critically ill and severe COVID-19 patients meet the diagnostic criteria for sepsis and even septic shock. The treatments for COVID-19 patients with sepsis are still very limited. For sepsis, improving ventilation is one of the main treatments. Nitric oxide (NO) and almitrine have been reported to improve oxygenation in patients with “classical” sepsis. Here, we conducted a systematic review and meta-analysis to evaluate the efficacy and safety of NO, almitrine, and the combination of both for COVID-19 (at the edge of sepsis) patients.</p><p><bold>Method:</bold> A systematic search was performed on Embase, PubMed, the Cochrane Library, the Web of Science, Wanfang Data, and China National Knowledge Infrastructure. Randomized clinical trials, cohort studies, cross-sectional studies, case-control studies, case series, and case reports in COVID-19 patients with suspected or confirmed sepsis were performed. Study characteristics, patient demographics, interventions, and outcomes were extracted from eligible articles.</p><p><bold>Results:</bold> A total of 35 studies representing 1,701 patients met eligibility criteria. Inhaled NO did not affect the mortality (OR 0.96, 95% CI 0.33–2.8, I<sup>2</sup> = 81%, very low certainty), hospital length of stay (SMD 0.62, 95% CI 0.04–1.17, I<sup>2</sup> = 83%, very low certainty), and intubation needs (OR 0.82, 95% CI 0.34–1.93, I<sup>2</sup> = 56%, very low certainty) of patients with COVID-19 (at the edge of sepsis). Meanwhile, almitrine did not affect the mortality (OR 0.44, 95% CI 0.17–1.13, low certainty), hospital length of stay (SMD 0.00, 95% CI -0.29–0.29, low certainty), intubation needs (OR 0.94, 95% CI 0.5–1.79, low certainty), and SAEs (OR 1.16, 95% CI 0.63–2.15, low certainty). Compared with pre-administration, the PaO<sub>2</sub>/FiO<sub>2</sub> of patients with NO (SMD-0.87, 95% CI -1.08–0.66, I<sup>2</sup> = 0%, very low certainty), almitrine (SMD-0.73, 95% CI-1.06–0.4, I<sup>2</sup> = 1%, very low certainty), and the combination of both (SMD-0.94, 95% CI-1.71–0.16, I<sup>2</sup> = 47%, very low certainty) increased significantly.</p><p><bold>Conclusion:</bold> Inhaled NO, almitrine, and the combination of the two drugs improved oxygenation significantly, but did not affect the patients’ mortality, hospitalization duration, and intubation needs. Almitrine did not significantly increase the patients’ SAEs. Well-designed high-quality studies are needed for establishing a stronger quality of evidence.</p><p><bold>Systematic Review Registration:</bold><ext-link ext-link-type="uri" xlink:href="https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=367667" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=367667</ext-link>, identifier CRD42022367667.</p>